ONCY Oncolytics Biotech, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
13:30
Aug 20
Aug 20
Buy ONCY on immune-priming mechanism, M&A potential
Buy ONCY on its pelareorep immune-priming platform that turns cold tumors hot, enhancing checkpoint inhibitors and supported by safety data from 1,300+ patients, making it a plausible Big Pharma partnership or acquisition target.
MED
08:36
Aug 20
Aug 20
ONCY safety profile and Fast Track noted
Highlights ONCY's 1,300-patient safety database and FDA Fast Track designations as reducing clinical development risk; no explicit buy/sell position stated.
LOW
08:00
Aug 20
Aug 20
FDA feedback supports ONCY registrational path
Reports FDA feedback supports ONCY's REO 033 trial path into registrational Part B and a possible accelerated-approval route; speaker stops short of an explicit directional commitment.
MED
07:30
Aug 20
Aug 20
ONCY more than single-indication platform story
Long ONCY on the view that pelareorep is a multi-indication dsRNA immunotherapy platform for GI tumors, backed by FDA Fast Track designations and safety data from 1,300+ patients, not just a single-asset story.
MED
About ONCY Analyst Coverage
Buzzberg tracks ONCY (Oncolytics Biotech, Inc.) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 4 total trade ideas tracked. Latest voices: pepinveststocks.